Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy (PAT) training courses uniquely selected to provide practitioners with complete PAT training, including an experiential component and practicum.
The company noted that the Certification Pathway develops core PAT skills through multi-modal teaching methods including interactive evidence and theory reviews, audio-visual design, case-based learning, experiential learning, in-person shadowing opportunities, and more.
Once all course requirements in the Certification Pathway are completed, trained practitioners will receive a formal certificate from Numinus to designate competency in providing PAT using specific medicines, the company said, adding that the Certification Pathway is designed to equip practitioners with the necessary skillset to deliver quality care to increase credibility and trust with clients.
READ: Numinus receives clinical trial application approval from Health Canada for experiential psychedelic-assisted therapy training using Psilocybe cubensis tea
"This is a unique opportunity for therapists and medical professionals to learn our PAT protocols and interact with our established Numinus practitioners as they share their real-life experiences in providing integrative and transformative mental wellness,” Numinus founder and CEO Payton Nyquvest said in a statement. "To date, more than 200 practitioners have completed Numinus practitioner training courses since they initially launched in Fall 2022.”
Courses that are part of the new Certification Pathway include:
- Fundamentals of Psychedelic-Assisted Therapy;
- Applied Psychedelic-Assisted Therapy: Cases, Conditions, and Context;
- Molecular Foundations of Ketamine, MDMA, and Psilocybin; and
- Practical Applications: Experiential Learning and Practicum.
Numinus said that, on average, 30 spaces are available to external practitioners in each course offered through the Numinus Certification Pathway. Courses run from four hours to eight weeks in length and are cohort-based– designed with busy practitioners in mind, with an easily customizable learning schedule.
Upon each course completion, practitioners are awarded a proof of completion certificate recognized by many accreditation bodies including the Canadian Psychological Association (CPA), the l'Ordre des psychologues du Québec (OPQ), the Canadian Counselling and Psychotherapy Association (CCPA) and the USA National Board for Certified Counsellors (NBCC).
Upon full completion of all courses outlined in the Numinus Certification Pathway, practitioners will be awarded a formal certificate to designate competency in providing PAT for the subject medicine, (for example, planned sources include Ketamine, Psilocybin or MDMA, subject to Health Canada approval).
The company noted that the most popular course, and core component of the Certification Pathway – 'The Fundamentals of Psychedelic-Assisted Therapy' is now taking registrations for its next intake, for May 2023. Through this eight-week virtual course program, practitioners will learn Numinus' model of care for psychedelic-assisted therapy – which is grounded in evidence, committed to client safety and rooted in justice, equity, dignity, and inclusion.
Numinus said its training team specializes in mindfulness, somatic, experiential and trauma-sensitive approaches, bringing a unique lens to this emerging field. Overall, it said this course will help equip mental health professionals and therapists with the foundational knowledge and skills to practice psychedelic-assisted therapy.
More details about the eight-week PAT course can be found here.
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.
Contact the author at stephen.gunnion@proactiveinvestors.com